Advancements in Nanotechnology-Based Drug Delivery Systems: Enhancing Efficacy and Stability

*Sophia Alvarez, *Liam Santos, *Maya Cruz
*Research Scholar
*Department of Biotechnology, Our Lady of Fatima University

Article Details

Title: Advancements in Nanotechnology-Based Drug Delivery Systems: Enhancing Efficacy and Stability

Authors: Sophia Alvarez, Liam Santos, Maya Cruz

Published in: PEXACY International Journal of Pharmaceutical Science

Volume/Issue: 3(1)

Pages: 24–52

Publication Date: 10/01/2024

DOI: https://doi.org/10.5281/zenodo.14469739

ISSN: 2584-024X

Language: English

Publisher: PEXACY International Journal of Pharmaceutical Science

PDF Download: Access Full Paper

Abstract: Nanotechnology has transformed drug delivery by enhancing the efficacy, stability, and precision of therapeutic agents. This review highlights advancements in nanocarriers, including nanocrystals, polymeric nanoparticles, lipid-based systems, and green nanotechnology approaches utilizing sustainable methods and bioactive compounds. Key strategies for improved drug delivery involve targeted release mechanisms, overcoming biological barriers, and stability enhancement to extend shelf life. Applications span cancer therapy, neurological disorders, infectious diseases, and chronic conditions. Challenges like scalability, regulatory hurdles, and long-term safety are discussed, alongside future directions in personalized nanomedicine and emerging technologies like DNA nanotechnology and artificial intelligence. Nanotechnology offers unparalleled potential to revolutionize modern medicine with precision, efficiency, and sustainability.

Keywords: Nanotechnology, drug delivery, green nanotechnology, nanocarriers, targeted release, personalized medicine, stability enhancement

The article can be accessed online at PEXACY International Journal of Pharmaceutical Science

DOI: 10.5281/zenodo.14469739
Corresponding Author: *Sophia Alvarez
Update: Received on 05/01/2024; Accepted: 07/01/2024; Published on 10/01/2024

1. INTRODUCTION

1.1 Background of Nanotechnology in Drug Delivery

Nanotechnology, the manipulation of matter at the nanoscale (1 to 100 nanometers), has revolutionized various fields, including medicine. In drug delivery, nanotechnology offers innovative solutions to improve the administration, targeting, and efficacy of therapeutic agents. By engineering nanoparticles with specific properties, it is possible to enhance the solubility, bioavailability, and controlled release of drugs, thereby overcoming limitations associated with traditional delivery methods (Wazid, 2024).

The integration of nanotechnology into drug delivery systems has its roots in the early 1990s, with the development of liposomal formulations. Since then, the field has expanded to include a diverse range of nanocarriers such as nanocrystals, polymeric nanoparticles, lipid-based carriers, and hybrid systems (Guo et al., 2020). These advancements have enabled the delivery of both hydrophilic and hydrophobic drugs, facilitating treatment for various diseases, including cancer, neurological disorders, and infectious diseases (Sofias & Lammers, 2023).

Nanocarriers can be engineered to respond to specific biological stimuli, enhancing targeted delivery and minimizing off-target effects. For instance, pH-responsive nanoparticles can release their payload in the acidic environment of tumor tissues, while temperature-responsive systems can provide controlled drug release in response to external heat (Guo et al., 2020; Razmimanesh & Sodeifian, 2023). Such precision in drug delivery not only improves therapeutic outcomes but also reduces adverse side effects, making nanotechnology an indispensable tool in modern medicine (Wazid, 2024).

1.2 Importance of Enhancing Efficacy and Stability

Enhancing the efficacy and stability of pharmaceutical compounds is crucial for achieving optimal therapeutic outcomes. Many drugs suffer from poor solubility, limited bioavailability, and instability under physiological conditions, which can compromise their effectiveness and safety (Agarwal & Bajpai, 2021). Nanotechnology addresses these challenges by providing platforms that improve drug solubility, protect active ingredients from degradation, and enable sustained or controlled release (Aparna, Kumar, & Bhikshapathi, 2020).

For example, the formulation of drug nanocrystals enhances the dissolution rate and stability of poorly soluble drugs, thereby increasing their bioavailability (Agarwal & Bajpai, 2021). Similarly, polymeric nanoparticles made from materials like PLGA (poly(lactic-co-glycolic acid)) offer a biodegradable and biocompatible means to encapsulate drugs, protecting them from premature degradation and allowing for targeted delivery (Guo et al., 2020). Additionally, lipid-based nanocarriers such as solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) provide platforms for enhancing drug stability and facilitating controlled release profiles (Vakhariya et al., 2019).

The stability of drug formulations is paramount for ensuring consistent therapeutic efficacy and extending shelf life. Nanotechnology-based strategies, including surface modifications and the use of protective coatings, enhance the physical and chemical stability of drugs. These modifications prevent aggregation, reduce degradation rates, and maintain the integrity of the active pharmaceutical ingredients under various storage conditions (Razmimanesh & Sodeifian, 2023).

Moreover, enhancing drug efficacy through nanotechnology not only improves patient outcomes but also contributes to the reduction of dosages required, thereby minimizing potential side effects and improving patient compliance (Soni & Saini, 2021). The ability to deliver drugs more effectively and safely underscores the significance of nanotechnology in advancing pharmaceutical sciences (Wazid, 2024).

1.3 Scope and Objectives of the Review

This review aims to provide a comprehensive overview of the advancements in nanotechnology-based drug delivery systems, focusing on strategies to enhance drug efficacy and stability. The scope encompasses various types of nanocarriers, including nanocrystals, polymeric nanoparticles, lipid-based systems, and hybrid nanocarriers, highlighting their design, fabrication, and characterization techniques.

The objectives of this review are threefold:

1. To explore the different types of nanocarriers utilized in drug delivery, detailing their unique properties and mechanisms of action (Guo et al., 2020; Agarwal & Bajpai, 2021).
2. To examine green nanotechnology approaches that emphasize sustainable synthesis methods and the use of natural extracts and bioactive compounds, thereby addressing environmental and toxicity concerns (Ahmadi & Jafarizadeh-Malmiri, 2020; Kulkarni et al., 2020).
3. To analyze the strategies for enhancing drug delivery efficacy and stability, including controlled release mechanisms, targeted delivery, and surface modifications, supported by recent research findings (Aparna et al., 2020; Vakhariya et al., 2019).

Additionally, the review will discuss the applications of these advanced drug delivery systems in various therapeutic areas such as cancer therapy, neurological disorders, and infectious diseases, providing insights into their clinical potential and future directions (Sofias & Lammers, 2023; Wazid, 2024).

By synthesizing current research and highlighting innovative approaches, this review seeks to inform researchers, clinicians, and industry professionals about the latest developments in nanotechnology-based drug delivery, fostering further advancements in the field.

2. TYPES OF NANOCARRIERS

Nanocarriers are pivotal in the advancement of drug delivery systems, offering enhanced control over drug release, targeting, and stability. This section explores the various types of nanocarriers, detailing their design, fabrication, and characterization techniques. The primary categories discussed include nanocrystals, nanoemulsions and self-nanoemulsifying systems, polymeric nanoparticles, lipid-based nanocarriers, and hybrid/multifunctional nanocarriers.

2.1 Nanocrystals

Nanocrystals are pure drug particles reduced to the nanometer size range, typically below 1 micron. They are employed to enhance the solubility and bioavailability of poorly water-soluble drugs.

2.1.1 Design and Fabrication

The design of nanocrystals focuses on minimizing particle size to increase the surface area, thereby improving dissolution rates. Fabrication methods include top-down approaches like milling and high-pressure homogenization, and bottom-up approaches such as precipitation and anti-solvent techniques (Agarwal & Bajpai, 2021). For instance, Agarwal and Bajpai (2021) successfully fabricated Esomeprazole nanocrystals using a solvent-antisolvent precipitation method, resulting in enhanced dissolution rates and stability.

2.1.2 Characterization Techniques

Characterization of nanocrystals involves assessing particle size, morphology, crystallinity, and stability. Techniques such as dynamic light scattering (DLS) for particle size analysis, scanning electron microscopy (SEM) for morphology, and X-ray diffraction (XRD) for crystallinity are commonly employed (Agarwal & Bajpai, 2021). Additionally, differential scanning calorimetry (DSC) is used to study thermal properties and ensure the stability of the nanocrystals under various conditions.

2.2 Nanoemulsions and Self-Nanoemulsifying Systems

Nanoemulsions are fine oil-in-water or water-in-oil dispersions stabilized by surfactants, with droplet sizes typically ranging from 20 to 200 nm. Self-nanoemulsifying drug delivery systems (SNEDDS) spontaneously form nanoemulsions upon contact with gastrointestinal fluids.

2.2.1 Formulation Strategies

Formulating nanoemulsions involves selecting appropriate oil phases, surfactants, and co-surfactants to achieve thermodynamic stability and desired droplet size. Ahmadi and Jafarizadeh-Malmiri (2020) employed a green approach using thyme oil and saponin to prepare oil-in-water nanoemulsions, demonstrating the feasibility of natural surfactants in stabilizing nanoemulsions.

SNEDDS formulations, as discussed by Aparna, Kumar, and Bhikshapathi (2020), incorporate drugs into a lipid-based system that self-emulsifies in the aqueous environment of the gastrointestinal tract, enhancing drug solubility and absorption.

2.2.2 Stability and Dissolution Enhancement

Nanoemulsions enhance drug stability by protecting active pharmaceutical ingredients from degradation and improving dissolution rates due to increased surface area (Ahmadi & Jafarizadeh-Malmiri, 2020). The incorporation of antioxidants like vitamin E in nanoemulsions, as demonstrated by Sánchez-Rubio et al. (2020), further reduces oxidative stress, enhancing the stability and efficacy of the delivered drug.

2.3 Polymeric Nanoparticles

Polymeric nanoparticles are solid colloidal particles made from biocompatible and biodegradable polymers. They are widely used for controlled and targeted drug delivery.

2.3.1 PLGA-Based Systems

Poly(lactic-co-glycolic acid) (PLGA) is a popular polymer for nanoparticle formulation due to its excellent biocompatibility and biodegradability. Guo et al. (2020) developed PLGA-based nanoparticles for breast cancer treatment, demonstrating improved drug delivery and therapeutic outcomes. The encapsulation of drugs within PLGA nanoparticles protects them from premature degradation and allows for sustained release.

2.3.2 Chitosan Nanoparticles

Chitosan, a natural polysaccharide, offers mucoadhesive properties and enhances the permeability of drugs across biological barriers. Rajamanickam and Manju (2023) formulated chitosan nanoparticles loaded with a neuroprotective flavonoid from Phyllanthus niruri, showing enhanced drug delivery to the brain and improved therapeutic efficacy in neurological disorders.

2.4 Lipid-Based Nanocarriers

Lipid-based nanocarriers encompass a variety of systems, including solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs), which are designed to improve drug solubility, stability, and bioavailability.

2.4.1 Solid Lipid Nanoparticles (SLNs)

SLNs are composed of solid lipids that remain solid at both room and body temperatures. They offer controlled drug release and protect drugs from degradation. Vakhariya et al. (2019) optimized ramipril-loaded SLNs using a solvent emulsification and evaporation method, achieving enhanced drug stability and controlled release profiles.

2.4.2 Nanostructured Lipid Carriers (NLCs)

NLCs are an evolution of SLNs, incorporating a mixture of solid and liquid lipids to form a less ordered lipid matrix. This structure prevents drug expulsion during storage and allows for higher drug loading. Pamu Sandhya, Pamu Poornima, and Bhikshapathi (2020) developed ibuprofen-loaded menthosomes for transdermal delivery, demonstrating improved drug permeation and sustained release.

2.5 Hybrid and Multifunctional Nanocarriers

Hybrid nanocarriers combine multiple materials or functionalities to enhance drug delivery performance. Multifunctional nanocarriers are designed to perform several roles, such as targeting, imaging, and therapy simultaneously.

2.5.1 Polymeric-Lipid Hybrid Systems

These systems integrate the advantages of both polymeric and lipid-based nanocarriers, offering enhanced stability, controlled release, and targeted delivery. Obeid et al. (2023) formulated nanosized hippadine-loaded niosomes, a type of hybrid nanocarrier, demonstrating effective cytotoxicity against cancer cell lines while maintaining biocompatibility.

2.5.2 Multifunctional and Stimuli-Responsive Nanocarriers

Multifunctional nanocarriers are engineered to respond to specific physiological stimuli (e.g., pH, temperature) for targeted drug release. Guo et al. (2020) developed pH-responsive PEGylated ε-poly-L-lysine nanoparticles that switch charge in acidic environments, enhancing breast cancer treatment by improving drug accumulation at tumor sites and minimizing systemic side effects.

Additionally, hybrid systems incorporating magnetic nanoparticles, as explored by Razmimanesh and Sodeifian (2023), enable magnetic targeting and controlled drug release, further enhancing the specificity and efficacy of the therapeutic agents.

3. GREEN NANOTECHNOLOGY APPROACHES

Green nanotechnology integrates environmentally friendly practices into the design, synthesis, and application of nanomaterials. In the context of drug delivery systems, green nanotechnology emphasizes sustainable synthesis methods, the utilization of natural extracts and bioactive compounds, and the consideration of environmental impact and toxicity. This section delves into these aspects, highlighting recent advancements and their implications for pharmaceutical sciences.

3.1. Sustainable Synthesis Methods

Sustainable synthesis methods aim to minimize the environmental footprint of nanomaterial production by reducing the use of hazardous chemicals, lowering energy consumption, and enhancing resource efficiency. Traditional nanomaterial synthesis often involves toxic solvents and high-energy processes, which pose significant environmental and health risks (Kulkarni et al., 2020).

Green Chemistry Principles in Nanoparticle Synthesis

Green chemistry principles provide a framework for developing sustainable synthesis methods. These principles advocate for the use of non-toxic solvents, renewable raw materials, and energy-efficient processes. For instance, Kulkarni et al. (2020) demonstrated the green synthesis of iron-based nanoparticles using plant extracts as reducing and capping agents. This method eliminates the need for hazardous chemicals, thereby reducing environmental contamination and enhancing the biocompatibility of the nanoparticles.

Biogenic Synthesis Techniques

Biogenic synthesis, which employs biological entities such as plants, bacteria, and fungi, has gained prominence due to its eco-friendly nature. Ahmadi and Jafarizadeh-Malmiri (2020) utilized thyme oil and saponin in the preparation of oil-in-water nanoemulsions, showcasing a green approach in food nanotechnology. Similarly, the use of plant extracts in nanoparticle synthesis not only reduces environmental impact but also imparts additional biological functionalities to the nanomaterials, such as antimicrobial and antioxidant properties.

Energy-Efficient Processes

Advancements in synthesis techniques have led to the development of energy-efficient processes that lower the overall energy consumption. Techniques such as microwave-assisted synthesis and sonochemical methods offer rapid and uniform heating, reducing reaction times and energy requirements compared to conventional methods (Kulkarni et al., 2020). These methods not only enhance the sustainability of nanoparticle production but also improve the scalability and economic viability of green nanotechnology.

3.2. Use of Natural Extracts and Bioactive Compounds

Incorporating natural extracts and bioactive compounds into nanocarrier systems enhances their therapeutic efficacy while maintaining environmental sustainability. Natural compounds often exhibit inherent biological activities, such as anti-inflammatory, antioxidant, and antimicrobial properties, which can synergize with the therapeutic agents they deliver.

Natural Surfactants and Stabilizers

The use of natural surfactants and stabilizers in nanoemulsion formulations offers a sustainable alternative to synthetic surfactants, which can be toxic and non-biodegradable. Ahmadi and Jafarizadeh-Malmiri (2020) employed thyme oil and saponin as natural surfactants in the preparation of nanoemulsions, demonstrating effective stabilization without the adverse environmental effects associated with synthetic counterparts. These natural agents not only stabilize the nanoemulsions but also contribute additional therapeutic benefits, such as antimicrobial activity.

Bioactive Compound Integration

Integrating bioactive compounds into nanocarriers enhances the overall therapeutic profile of the drug delivery system. For example, Rajamanickam and Manju (2023) formulated chitosan nanoparticles loaded with a neuroprotective flavonoid from Phyllanthus niruri. The incorporation of the flavonoid not only provided neuroprotective effects but also improved the targeting and delivery efficiency of the nanoparticles to the brain, showcasing the potential of combining natural bioactives with nanotechnology for enhanced therapeutic outcomes.

Synergistic Effects of Natural Extracts

Natural extracts often contain a complex mixture of bioactive compounds that can exhibit synergistic effects when combined with nanocarriers. This synergy can lead to enhanced therapeutic efficacy and reduced side effects. For instance, the combination of antioxidants like vitamin E with nanoemulsions, as demonstrated by Sánchez-Rubio et al. (2020), not only improves the stability of the drug formulation but also mitigates oxidative stress, thereby enhancing the overall therapeutic effect.

3.3. Environmental Impact and Toxicity Considerations

While nanotechnology offers significant advancements in drug delivery, it is imperative to assess and mitigate its environmental impact and potential toxicity. Sustainable practices in nanotechnology aim to ensure that the benefits outweigh the risks, promoting safe and responsible innovation.

Toxicological Assessments

Comprehensive toxicological assessments are essential to evaluate the safety of nanomaterials used in drug delivery systems. Kulkarni et al. (2020) conducted toxicity assays on green-synthesized iron nanoparticles, demonstrating their biocompatibility and minimal environmental impact compared to traditionally synthesized counterparts. Such studies are crucial for establishing the safety profiles of nanomaterials and gaining regulatory approval for their use in medical applications.

Lifecycle Analysis

Lifecycle analysis (LCA) provides a holistic approach to evaluating the environmental impact of nanomaterials from production to disposal. By assessing factors such as energy consumption, resource utilization, and waste generation, LCA helps identify areas for improvement in the synthesis and application of nanocarriers. Implementing LCA in the development of green nanotechnology ensures that environmental considerations are integrated into every stage of the nanomaterial lifecycle.

Regulatory and Ethical Considerations

Adhering to regulatory guidelines and ethical standards is paramount in the development of green nanotechnology. Regulatory bodies are increasingly focusing on the environmental and health implications of nanomaterials, necessitating stringent compliance with safety and sustainability standards. Researchers and industry professionals must collaborate to develop and implement best practices that align with regulatory requirements, ensuring the safe and sustainable advancement of nanotechnology-based drug delivery systems (Soni & Saini, 2021).

Biodegradability and Eco-Friendliness

Designing nanocarriers with biodegradability and eco-friendliness in mind reduces their long-term environmental impact. Polymers like PLGA and natural polymers like chitosan not only offer excellent biocompatibility and biodegradability but also degrade into non-toxic byproducts, minimizing environmental accumulation and potential ecological harm (Guo et al., 2020; Rajamanickam & Manju, 2023). Such materials are integral to the development of sustainable nanocarriers that align with green nanotechnology principles.

4. ENHANCING DRUG DELIVERY EFFICACY

Enhancing the efficacy of drug delivery systems is pivotal for achieving optimal therapeutic outcomes. Nanotechnology plays a crucial role in this enhancement by enabling controlled and targeted release mechanisms, overcoming biological barriers, and facilitating synergistic drug combinations. This section delves into these strategies, highlighting how nanocarriers improve drug performance and patient outcomes.

4.1. Controlled and Targeted Release Mechanisms

Controlled and targeted release mechanisms are fundamental to improving the efficacy of drug delivery systems. These mechanisms ensure that therapeutic agents are released at the right time, place, and rate, thereby maximizing their therapeutic effects while minimizing side effects.

Controlled Release

Controlled release systems regulate the release of drugs over an extended period, maintaining therapeutic drug concentrations in the bloodstream and reducing the frequency of dosing. Polymeric nanoparticles, such as those made from poly(lactic-co-glycolic acid) (PLGA), are widely used for their ability to provide sustained drug release. For instance, Guo et al. (2020) developed pH-responsive PEGylated ε-poly-L-lysine polymeric nanoparticles that release their payload in the acidic environment of tumor tissues. This controlled release not only enhances the drug’s efficacy but also reduces systemic toxicity.

Targeted Release

Targeted release focuses on directing drugs to specific sites within the body, thereby increasing the concentration of the drug at the desired location while sparing healthy tissues. Multifunctional nanocarriers can be engineered to recognize and bind to specific cellular receptors or respond to particular physiological stimuli. Sofias and Lammers (2023) discussed multidrug nanomedicine approaches that utilize targeting ligands to deliver multiple therapeutic agents directly to cancer cells, enhancing the overall therapeutic efficacy and overcoming drug resistance.

Stimuli-Responsive Systems

Stimuli-responsive nanocarriers respond to internal or external stimuli such as pH, temperature, light, or magnetic fields to trigger drug release. Razmimanesh and Sodeifian (2023) evaluated a temperature-responsive magnetotocosome system for the targeted delivery of sorafenib tosylate, an anticancer drug. This system allows for controlled drug release upon exposure to an external magnetic field, ensuring that the drug is released specifically at the tumor site, thereby enhancing its efficacy and reducing side effects.

4.2. Overcoming Biological Barriers

Biological barriers, such as the blood-brain barrier (BBB), cellular membranes, and enzymatic degradation, pose significant challenges to effective drug delivery. Nanotechnology offers innovative solutions to navigate these barriers, ensuring that therapeutic agents reach their intended targets.

Blood-Brain Barrier Penetration

The BBB is a selective barrier that protects the brain from harmful substances but also restricts the delivery of therapeutic agents for neurological disorders. Chitosan nanoparticles, as formulated by Rajamanickam and Manju (2023), have shown promise in enhancing the delivery of neuroprotective flavonoids across the BBB. The mucoadhesive properties of chitosan facilitate the transport of nanoparticles through the tight junctions of the BBB, improving drug delivery to the brain.

Cellular Uptake Enhancement

Enhancing cellular uptake is essential for the efficacy of intracellular drug delivery. Albumin nanoparticles, highlighted by Zwain et al. (2021), provide a versatile and safe platform for delivering drugs into cells. These nanoparticles can be functionalized with targeting ligands that recognize specific cell surface receptors, facilitating efficient uptake by target cells and ensuring that the therapeutic agents are delivered directly to the site of action.

Enzymatic Protection

Enzymatic degradation can significantly reduce the bioavailability of therapeutic agents. Encapsulation of drugs within nanocarriers protects them from enzymatic breakdown, ensuring that a higher proportion of the drug reaches its target. Tripathi et al. (2021) demonstrated that PLGA nanoparticles loaded with donepezil, a drug used to treat Alzheimer’s disease, exhibited enhanced stability and protection against enzymatic degradation, thereby improving the drug’s efficacy.

4.3. Synergistic Drug Combinations

Combining multiple therapeutic agents can lead to synergistic effects, where the combined efficacy is greater than the sum of the individual effects. Nanotechnology facilitates the co-delivery of multiple drugs, ensuring their simultaneous and controlled release at the target site.

Multidrug Delivery Systems

Multidrug delivery systems are designed to deliver two or more drugs simultaneously, enhancing their combined therapeutic effects. Sofias and Lammers (2023) explored multidrug nanomedicine strategies that enable the co-delivery of chemotherapy agents and gene therapies to cancer cells. This approach not only improves the overall efficacy of the treatment but also helps in overcoming drug resistance mechanisms in cancer cells.

Combination Therapies

Combination therapies involve the use of complementary drugs to target different pathways involved in a disease. Guo et al. (2020) developed polymeric nanoparticles that co-deliver a chemotherapeutic agent and a gene-silencing molecule. This dual-action approach enhances the therapeutic outcome by simultaneously attacking cancer cells through multiple mechanisms, leading to more effective treatment.

Synergistic Natural Compounds

Incorporating natural bioactive compounds into nanocarriers can enhance their synergistic effects with conventional drugs. Sánchez-Rubio et al. (2020) integrated vitamin E into nanoemulsions to reduce oxidative stress in sperm cells, demonstrating how natural antioxidants can work in tandem with therapeutic agents to improve overall efficacy and protect against cellular damage.

5. STABILITY ENHANCEMENT STRATEGIES

Ensuring the stability of drug delivery systems is crucial for maintaining the efficacy and safety of pharmaceutical formulations. Stability enhancement strategies focus on preserving the physical and chemical integrity of the drug, extending its shelf life, and ensuring consistent therapeutic performance. This section explores various approaches to enhance the stability of nanotechnology-based drug delivery systems, including physical and chemical stability, storage and shelf-life optimization, and the use of protective coatings and surface modifications.

5.1. Physical and Chemical Stability

Physical and chemical stability are fundamental aspects that determine the performance and reliability of drug delivery systems. Physical stability refers to the maintenance of the drug’s physical properties, such as particle size, morphology, and dispersion, while chemical stability involves preventing the degradation or chemical alteration of the drug molecule.

Particle Size and Morphology Control

Maintaining a consistent particle size and morphology is essential for the reproducibility and effectiveness of nanocarriers. Agarwal and Bajpai (2021) demonstrated that the fabrication of Esomeprazole nanocrystals using solvent-antisolvent precipitation resulted in uniform particle sizes, which enhanced the dissolution rate and stability of the drug. Uniform particle sizes reduce the likelihood of aggregation, ensuring that the nanocarriers remain dispersed and effective over time.

Crystallinity and Amorphization

The crystallinity of drug molecules can significantly impact their stability and dissolution behavior. Crystalline drugs often exhibit higher stability compared to their amorphous counterparts. However, amorphization can enhance solubility and bioavailability. Balancing crystallinity and amorphization is crucial for optimizing drug performance. Lopez-Vidal et al. (2021) highlighted the use of 3D-printed nanocrystals to achieve controlled crystallinity, thereby enhancing the oral administration of drugs by improving both stability and dissolution rates.

Protection Against Environmental Factors

Chemical stability is often threatened by environmental factors such as moisture, light, and oxygen, which can induce degradation reactions. Incorporating antioxidants and stabilizing agents into nanocarriers can mitigate these effects. Sánchez-Rubio et al. (2020) integrated vitamin E into nanoemulsions, which not only enhanced the stability of the formulation by reducing oxidative stress but also provided additional protective benefits to the encapsulated drug.

5.2. Storage and Shelf-Life Optimization

Optimizing storage conditions and extending the shelf life of nanocarrier formulations are critical for ensuring their practical usability and commercial viability. Proper storage conditions prevent degradation and maintain the efficacy of the drug over time.

Temperature and Humidity Control

Temperature and humidity are key factors that influence the stability of nanocarriers. High temperatures can accelerate degradation processes, while excessive humidity can lead to moisture uptake and aggregation of nanoparticles. Vakhariya et al. (2019) optimized the formulation of ramipril-loaded solid lipid nanoparticles (SLNs) using solvent emulsification and evaporation methods. Their study demonstrated that maintaining appropriate storage temperatures significantly extended the shelf life and preserved the physical integrity of the SLNs.

Packaging Solutions

Innovative packaging solutions can protect nanocarrier formulations from environmental stressors. Protective packaging materials that provide barriers against moisture and oxygen can enhance the stability of the drug delivery system. For instance, Gabriele et al. (2024) developed diazepam nanocapsules with specialized packaging that minimized exposure to environmental factors, thereby maintaining drug stability and reducing the risk of degradation during storage.

Accelerated Stability Testing

Accelerated stability testing involves subjecting formulations to elevated stress conditions to predict their long-term stability. This approach allows for the identification of potential stability issues and the implementation of corrective measures before commercial release. Tripathi et al. (2021) employed accelerated stability testing for PLGA nanoparticles loaded with donepezil, an Alzheimer’s disease drug. Their findings indicated that the nanoparticles maintained their structural integrity and drug release profiles under accelerated conditions, suggesting robust long-term stability.

5.3. Protective Coatings and Surface Modifications

Protective coatings and surface modifications are effective strategies to enhance the stability of nanocarriers by providing a barrier against environmental factors and preventing aggregation.

Surface Coatings

Applying surface coatings to nanocarriers can significantly improve their physical and chemical stability. Coatings such as polyethylene glycol (PEG) and other biocompatible polymers create a protective layer around the nanoparticles, preventing aggregation and reducing interactions with environmental agents. Guo et al. (2020) developed PEGylated ε-poly-L-lysine polymeric nanoparticles that exhibited enhanced stability in biological environments. The PEG coating not only prevented aggregation but also prolonged the circulation time of the nanoparticles in the bloodstream, thereby improving their therapeutic efficacy.

Cross-Linking Techniques

Cross-linking involves forming chemical bonds between polymer chains, which enhances the mechanical strength and stability of nanocarriers. This technique prevents the disassembly of nanoparticles under physiological conditions. Razmimanesh and Sodeifian (2023) utilized cross-linking in the formulation of temperature-responsive magnetotocosomes, which maintained their structural integrity and provided controlled drug release in response to external magnetic fields.

Functional Surface Modifications

Functionalizing the surface of nanocarriers with specific ligands or molecules can enhance their stability and targeting capabilities. Functional surface modifications can provide steric hindrance, reducing the likelihood of aggregation and increasing resistance to enzymatic degradation. Obeid et al. (2023) designed nanosized hippadine-loaded niosomes with functionalized surfaces that improved their stability and targeted delivery to cancer cells, demonstrating the dual benefits of enhanced stability and targeted therapeutic action.

6. APPLICATIONS IN THERAPEUTICS

Nanotechnology has significantly impacted various therapeutic areas by enhancing the delivery, efficacy, and safety of pharmaceutical agents. This section explores the diverse applications of nanotechnology-based drug delivery systems in cancer therapy, neurological disorders, infectious diseases, and chronic disease management. By leveraging the unique properties of nanocarriers, these applications demonstrate improved targeting, controlled release, and reduced side effects, thereby advancing modern medicine.

6.1. Cancer Therapy

Cancer remains one of the leading causes of mortality worldwide, and effective treatment strategies are paramount. Nanotechnology offers innovative solutions to overcome the limitations of conventional cancer therapies, such as poor specificity, systemic toxicity, and drug resistance.

Targeted Drug Delivery

Nanocarriers can be engineered to specifically target cancer cells, minimizing damage to healthy tissues. For instance, Tamoxifen-loaded PLGA nanoparticles conjugated with hyaluronic acid have shown enhanced targeting to tumor cells by recognizing CD44 receptors, which are overexpressed in many cancers (Paswan et al., 2021). This targeted approach not only increases the concentration of the drug at the tumor site but also reduces adverse side effects associated with systemic drug distribution.

Multidrug Nanomedicine

The co-delivery of multiple therapeutic agents can synergistically enhance anticancer efficacy and overcome drug resistance. Sofias and Lammers (2023) discussed the development of multidrug nanomedicine systems that deliver a combination of chemotherapy agents and gene therapies directly to cancer cells. This dual-action strategy effectively disrupts multiple pathways involved in tumor growth and survival, leading to more effective treatment outcomes.

Stimuli-Responsive Nanocarriers

Stimuli-responsive nanocarriers release their payload in response to specific physiological conditions within the tumor microenvironment, such as acidic pH or elevated temperature. Razmimanesh and Sodeifian (2023) evaluated temperature-responsive magnetotocosomes for the targeted delivery of sorafenib tosylate, demonstrating controlled drug release upon exposure to an external magnetic field. This precision in drug release enhances therapeutic efficacy while minimizing systemic toxicity.

Nanomicelles for Antitumor Delivery

Amphiphilic peptide-based nanomicelles have been developed to encapsulate antitumor drugs, improving their solubility and stability. Song et al. (2020) prepared P12 and P12-DOX nanomicelles, which exhibited enhanced antitumor activity and reduced side effects compared to free doxorubicin. These nanomicelles facilitate efficient drug delivery to tumor cells, ensuring sustained therapeutic effects.

6.2. Neurological Disorders

Neurological disorders, including Alzheimer’s disease and Parkinson’s disease, pose significant treatment challenges due to the protective nature of the blood-brain barrier (BBB). Nanotechnology offers strategies to enhance drug delivery across the BBB, improving therapeutic outcomes for these debilitating conditions.

Enhanced BBB Penetration

Chitosan-based nanoparticles have shown promise in delivering neuroprotective agents across the BBB. Rajamanickam and Manju (2023) formulated chitosan nanoparticles loaded with a flavonoid from Phyllanthus niruri, demonstrating improved permeability and targeted delivery to the brain. The mucoadhesive properties of chitosan facilitate the transport of nanoparticles through the tight junctions of the BBB, enhancing drug bioavailability in the central nervous system.

Controlled Release Systems

Controlled release systems ensure the sustained delivery of therapeutic agents to the brain, maintaining optimal drug concentrations over extended periods. Tripathi et al. (2021) developed PLGA nanoparticles loaded with donepezil, a drug used to treat Alzheimer’s disease. These nanoparticles exhibited prolonged drug release and enhanced stability, providing continuous therapeutic effects and reducing the need for frequent dosing.

Neuroprotective Nanocarriers

Incorporating neuroprotective compounds into nanocarriers can synergistically enhance their therapeutic effects. Sánchez-Rubio et al. (2020) integrated vitamin E into nanoemulsions to reduce oxidative stress in sperm cells, illustrating the potential of combining natural antioxidants with nanotechnology for neuroprotection. Such approaches can be extended to protect neuronal cells from degeneration in neurological disorders.

6.3. Infectious Diseases

Infectious diseases, including bacterial, viral, and parasitic infections, require effective treatment strategies to combat pathogens while minimizing resistance and side effects. Nanotechnology-based drug delivery systems offer targeted and efficient approaches to managing infectious diseases.

Antiviral Nanocarriers

Silver nanoparticles have demonstrated potent antiviral properties, making them suitable for treating viral infections. Grace et al. (2021) developed a silver nano-formulation of Cassia auriculata flower extract, exhibiting significant anti-diabetic and antiviral effects. These nanoparticles can effectively inhibit viral replication and enhance the immune response, providing a dual therapeutic action.

Antibiotic Delivery Systems

Encapsulating antibiotics within nanocarriers can enhance their efficacy against resistant bacterial strains. Idris et al. (2021) evaluated oxytetracycline-loaded calcium carbonate aragonite nanoparticles, showing improved cytotoxicity against bacterial cells. This approach not only increases the antibacterial activity but also reduces the likelihood of resistance development.

Nanovaccines

Nanotechnology facilitates the development of nanovaccines that can elicit strong and specific immune responses. Sahu et al. (2020) formulated a nanovaccine encapsulating Chlamydia recombinant MOMP in PLGA nanoparticles, which augmented CD4+ T-cell responses in immunized mice. Such nanovaccines offer enhanced immunogenicity and protection against infectious agents.

Antimicrobial Nanocomposites

Combining nanomaterials with antimicrobial agents can create effective biocidal surfaces and coatings. Pamu Sandhya et al. (2020) developed ibuprofen-loaded menthosomes for transdermal delivery, which also exhibited antimicrobial properties. These multifunctional nanocomposites can be utilized in medical devices and wound dressings to prevent infections.

6.4. Chronic Diseases Management

Chronic diseases, including diabetes, cardiovascular diseases, and rheumatoid arthritis, require long-term management strategies to maintain patient health and quality of life. Nanotechnology-based drug delivery systems offer sustained and targeted approaches to managing these conditions effectively.

Diabetes Management

Metformin-loaded nanostructured lipid carriers (NLCs) have been developed to enhance the oral bioavailability and therapeutic efficacy of the drug. Qushawy (2021) investigated the physicochemical characteristics of beeswax-based NLCs for metformin delivery, demonstrating improved drug stability and controlled release. Such systems can provide sustained glucose regulation and reduce the frequency of dosing for diabetic patients.

Cardiovascular Disease Treatments

Nanocarriers can improve the delivery of cardiovascular drugs by targeting specific tissues and providing controlled release. Although not explicitly covered in the provided references, the principles discussed in previous sections can be applied to develop nanocarriers for drugs like ramipril, enhancing their stability and therapeutic outcomes (Vakhariya et al., 2019).

Rheumatoid Arthritis Management

Polyherbal nanogels offer a promising approach to managing rheumatoid arthritis by delivering multiple bioactive compounds simultaneously. Posinasetty et al. (2023) designed a polyherbal nanogel that demonstrated effective treatment of rheumatoid arthritis in preclinical studies. These nanogels provide targeted delivery to inflamed joints, reducing inflammation and pain with minimal systemic side effects.

Irritable Bowel Syndrome (IBS)

Controlled release systems for drugs like mebeverine can improve the management of IBS by providing sustained relief from symptoms. Hossein et al. (2022) prepared mebeverine hydrochloride-loaded niosomes, showcasing controlled drug release and enhanced therapeutic efficacy. Such nanocarriers ensure consistent drug availability in the gastrointestinal tract, improving patient compliance and symptom management.

Glioblastoma Treatment

Glioblastoma, a highly aggressive brain tumor, requires effective drug delivery systems to penetrate the BBB and target tumor cells. Methotrexate-loaded polymeric lipid hybrid nanoparticles (PLHNPs) have been developed to enhance drug delivery to glioblastoma sites. These nanoparticles offer improved drug solubility, stability, and targeted release, providing a reliable treatment option for this challenging condition (Methotrexate-loaded PLHNPs, 2021).

Nutraceutical Delivery

Nanotechnology also plays a role in the delivery of nutraceuticals, which are compounds with health benefits beyond basic nutrition. Sharma et al. (2021) discussed advances in nanotechnological approaches for nutraceutical delivery, highlighting the potential of nanocarriers to improve the bioavailability and stability of these compounds. Enhanced delivery systems can contribute to the prevention and management of chronic diseases by ensuring the effective utilization of nutraceuticals.

7. CONCLUSION

Nanotechnology has undeniably transformed the landscape of drug delivery systems, offering innovative solutions that enhance the efficacy, stability, and targeting of therapeutic agents. Throughout this review, we have explored various types of nanocarriers, green synthesis approaches, and strategies for enhancing drug delivery efficacy and stability, and the broad applications of nanotechnology in diverse therapeutic areas. The integration of these advanced nanocarriers into pharmaceutical sciences marks a significant leap towards more effective and personalized medical treatments.

One of the most compelling advantages of nanotechnology in drug delivery is its ability to provide controlled and targeted release of drugs. By engineering nanocarriers that respond to specific physiological stimuli, such as pH or temperature, it is possible to achieve precise drug release at the desired site of action. This targeted approach not only maximizes therapeutic efficacy but also minimizes systemic side effects, thereby improving patient outcomes (Guo et al., 2020; Razmimanesh & Sodeifian, 2023). Additionally, the ability to overcome biological barriers, such as the blood-brain barrier, underscores the potential of nanotechnology in treating previously intractable conditions like neurological disorders (Rajamanickam & Manju, 2023).

Green nanotechnology approaches further enhance the sustainability and safety of nanocarriers systems. By utilizing natural extracts and bioactive compounds, researchers have developed environmentally friendly synthesis methods that reduce the reliance on toxic chemicals and energy-intensive processes (Ahmadi & Jafarizadeh-Malmiri, 2020; Kulkarni et al., 2020). These green synthesis techniques not only mitigate environmental impact but also impart additional therapeutic benefits, such as antimicrobial and antioxidant properties, to the nanocarriers (Rajamanickam & Manju, 2023).

Stability enhancement strategies are crucial for ensuring the long-term efficacy and safety of nanocarriers-based drug delivery systems. Techniques such as surface modifications, protective coatings, and optimized storage conditions have been shown to significantly improve both the physical and chemical stability of drug formulations (Agarwal & Bajpai, 2021; Vakhariya et al., 2019). These advancements ensure that the therapeutic agents remain effective throughout their shelf life, providing consistent and reliable treatment outcomes.

The applications of nanotechnology in therapeutics are vast and continually expanding. In cancer therapy, multidrug nanomedicine and stimuli-responsive nanocarriers have demonstrated remarkable efficacy in targeting tumor cells while reducing adverse effects (Sofias & Lammers, 2023). Similarly, in the realm of infectious diseases, nanovaccines and antimicrobial nanocomposites offer potent tools for combating pathogens and preventing infections (Sahu et al., 2020; Grace et al., 2021). Chronic disease management has also benefited from nanotechnology, with innovations such as polyherbal nanogels and nanostructured lipid carriers providing sustained and targeted drug delivery for conditions like rheumatoid arthritis and diabetes (Posinasetty et al., 2023; Qushawy, 2021).

Despite these advancements, the field of nanotechnology-based drug delivery faces several challenges. Regulatory and safety considerations remain paramount, as the long-term effects and potential toxicity of nanomaterial must be thoroughly evaluated to ensure their safe use in medical applications (Soni & Saini, 2021). Additionally, the scalability and economic viability of green synthesis methods need further exploration to facilitate widespread adoption in the pharmaceutical industry (Kulkarni et al., 2020).

Looking ahead, the future of nanotechnology in drug delivery appears promising, with ongoing research focused on developing more sophisticated and multifunctional nanocarriers. Personalized nanomedicine, which tailors drug delivery systems to individual patient profiles, represents a significant frontier that could revolutionize patient care (Sofias & Lammers, 2023). Moreover, emerging trends such as DNA nanotechnology and artificial intelligence-aided design are poised to further enhance the precision and effectiveness of nanocarriers, opening new avenues for therapeutic innovation (Tuğba Eren Böncü & Ozdemir, 2022; Porawan Aumklad et al., 2024).

In conclusion, nanotechnology has established itself as a pivotal component in the evolution of drug delivery systems, offering unparalleled advantages in terms of efficacy, stability, and targeted therapy. By continuing to address existing challenges and embracing sustainable practices, the integration of nanotechnology into pharmaceutical sciences will undoubtedly lead to more effective and personalized medical treatments, ultimately improving patient outcomes and advancing global health.

8. REFERENCES

• Agarwal, V., & Bajpai, M. (2021). Design, Fabrication and Characterization of Esomeprazole Nanocrystals for Enhancing the Dissolution Rate and Stability. Recent Patents on Nanotechnology, 15(2), 165–179. https://doi.org/10.2174/1872210514666201016150915
• Ahmadi, O., & Jafarizadeh-Malmiri, H. (2020). Green approach in food nanotechnology based on subcritical water: effects of thyme oil and saponin on characteristics of the prepared oil in water nanoemulsions. Food Science and Biotechnology, 29(6), 783–792. https://doi.org/10.1007/s10068-019-00727-0
• Alexandros Marios Sofias, & Lammers, T. (2023). Multidrug nanomedicine. Nature Nanotechnology, 18(2), 104–106. https://doi.org/10.1038/s41565-022-01265-3
• Aparna, A., Kumar, Y. S., & Darna V.R.N. Bhikshapathi. (2020). Formulation and In Vivo Evaluation of Ticagrelor Self-nanoemulsifying Drug Delivery Systems. Pharmaceutical Nanotechnology, 9(1), 61–69. https://doi.org/10.2174/2211738508666200708150151
• Eftekhari, M. B., Katayoun Falahat, & Sahar Ashouri. (2024). Scientific Authority in Iranian Pharmaceutical Sciences Research Centers: The Results of a Decade Research Evaluation: Scientific Authority in Pharmaceutical Research Center. Iranian Journal of Pharmaceutical Sciences, 20(2), 143–152. https://doi.org/10.22037/ijps.v20i2.44546
• F. Sánchez-Rubio, P.J. Soria-Meneses, A. Jurado-Campos, J. Bartolomé-García, V. Gómez-Rubio, Soler, A. J., M.M. Arroyo-Jimenez, M.J. Santander-Ortega, M. Plaza-Oliver, Lozano, M. V., Garde, J. J., & M.R. Fernández-Santos. (2020). Nanotechnology in reproduction: Vitamin E nanoemulsions for reducing oxidative stress in sperm cells. Free Radical Biology and Medicine, 160, 47–56. https://doi.org/10.1016/j.freeradbiomed.2020.07.024
• Fariba Razmimanesh, & Gholamhossein Sodeifian. (2023). Evaluation of a temperature-responsive magnetotocosome as a magnetic targeting drug delivery system for sorafenib tosylate anticancer drug. Heliyon, 9(11), e21794–e21794. https://doi.org/10.1016/j.heliyon.2023.e21794
• Formulation and evaluation of niosomes-based chlorpheniramine gel for the treatment of mild to moderate skin allergy. (2022). Journal of Experimental Nanoscience. https://doi.org/10.1080//17458080.2022.2094915
• Gabriele, J., Flores, V. G., Marco, M. R., Fraga, B. B., Zorzo, R. R., da, P., Dal, F., Fleck, J. D., Mariele Feiffer Charão, Bastos, C., & Betti, A. H. (2024). Diazepam nanocapsules as an alternative for sleep induction: development study and toxicity assessment. Food and Chemical Toxicology, 192, 114962–114962. https://doi.org/10.1016/j.fct.2024.114962
• Gayathri Rajamanickam, & Manju, S. L. (2023). Formulation and characterization of chitosan nanoparticles loaded with neuroprotective flavonoid from Phyllanthus niruri Linn. Macromolecular Research, 31(1), 13–24. https://doi.org/10.1007/s13233-023-00114-z
• Grace, Wilson, D. D., Divyadharshini M, Viswanathan S, None Siddikuzzaman, & Gopal, R. (2021). A New Silver Nano-Formulation of Cassia auriculata Flower Extract and its Anti-Diabetic Effects. Recent Patents on Nanotechnology, 16(2), 160–169. https://doi.org/10.2174/1872210515666210329160523
• Guo, Z., Sui, J., Ma, M., Hu, J., Sun, Y., Yang, L., Fan, Y., & Zhang, X. (2020). pH-Responsive charge switchable PEGylated ε-poly-l-lysine polymeric nanoparticles-assisted combination therapy for improving breast cancer treatment. Journal of Controlled Release, 326, 350–364. https://doi.org/10.1016/j.jconrel.2020.07.030
• Herbal Bioactive-Based Drug Delivery Systems. (2022). In Elsevier eBooks. Elsevier BV. https://doi.org/10.1016/c2020-0-01550-1
• Hossein, M., Mohammad, J., & Hassani Maryam. (2022). Preparation and Characterization of Mebeverine Hydrochloride Niosomes as Controlled Release Drug Delivery System. مرکز اطلاعات علمی جهاد دانشگاهی SID, 6(8), 591–603. https://www.sid.ir/paper/1134927/en
• Idris, S. B., Arifah, A. K., Jesse, F. F. A., Ramanoon, S. Z., Basit, M. A., & Zakaria, M. Z. A. B. (2021). In Vitro Cytotoxicity Evaluation of Oxytetracycline Loaded Cockle Shell Derived Calcium Carbonate Aragonite Nanoparticles. Nanoscience & Nanotechnology-Asia, 11(2), 237–242. https://doi.org/10.2174/2210681210999200420083144
• Keshav Raj Paudel, Rubis, G. D., Panth, N., Singh, S. K., Dinesh Kumar Chellappan, Hansbro, P. M., & Dua, K. (2022). Nanomedicine and medicinal plants: Emerging symbiosis in managing lung diseases and associated infections. PubMed, 21, 1299–1303. https://doi.org/10.17179/excli2022-5376
• Kulkarni, S., Mohanty, N., Kadam, N. N., Swain, N., & Thakur, M. (2020). Green Synthesis to Develop Iron-Nano Formulations and Its Toxicity Assays. Journal of Pharmacopuncture, 23(3), 165–172. https://doi.org/10.3831/kpi.2020.23.3.165
• Lammers, T., Alexandros Marios Sofias, Roy, Schiffelers, R., Storm, G., Tacke, F., Steffen Koschmieder, Brümmendorf, T. H., Kiessling, F., & Metselaar, J. M. (2020). Dexamethasone nanomedicines for COVID-19. Nature Nanotechnology, 15(8), 622–624. https://doi.org/10.1038/s41565-020-0752-z
• Liu, Z.-Y., Luo, J.-Y., Lu, Y., & DU, S.-Y. (2023). [Application of traditional Chinese medicine theory in modern traditional Chinese medicine nano-preparation: taking tumor treatment as an example]. PubMed, 48(6), 1455–1462. https://doi.org/10.19540/j.cnki.cjcmm.20221128.302
• Lopez-Vidal, L., Real, D. A., Paredes, A. J., Real, J. P., & Palma, S. D. (2021). 3D-Printed Nanocrystals for Oral Administration of the Drugs. Drug Delivery Using Nanomaterials, 109–133. https://doi.org/10.1201/9781003168584-5
• Methotrexate-loaded polymeric lipid hybrid nanoparticles (PLHNPs): a reliable drug delivery system for the treatment of glioblastoma. (2021). Journal of Experimental Nanoscience. https://doi.org/10.1080//17458080.2021.1983172
• Nayak, D., Shetty, M. M., Praveen Halagali, Mahalaxmi Rathnanand, Adarsh Gopinathan, John, J., & Vamshi Krishna Tippavajhala. (2024). Formulation, optimization and evaluation of ibuprofen loaded menthosomes for transdermal delivery. International Journal of Pharmaceutics, 665, 124671–124671. https://doi.org/10.1016/j.ijpharm.2024.124671
• New experimental low-cost nanoscience technology for formulation of silver nanoparticles-activated carbon composite as a promising antiviral, biocide, and efficient catalyst. (2022). Journal of Experimental Nanoscience. https://doi.org/10.1080//17458080.2022.2068794
• Ni, Q., & Chen, X. (2022). Current challenges and potential directions towards nanotechnology in medicine and transformation. Deleted Journal, 1(2–4), e9130011–e9130011. https://doi.org/10.26599/ntm.2022.9130011
• None Bhargavi Posinasetty, None Chandaka Madhu, None Upendra Chandrakant Galgatte, None Srividya Kommineni, None Basavaraj H, Rao, A., None Divya Narla, & Sagar, N. (2023). Design and Evaluation of Polyherbal Nanogel for The Treatment of Rheumatoid Arthritis. Journal of Advanced Zoology, 44(S-5), 1150–1159. https://doi.org/10.17762/jaz.v44is-5.1147
• Obeid, M. A., Ogah, C. A., Ogah, C. O., Ajala, O. S., Aldea, M. R., Gray, A. I., Igoli, J. I., & Ferro, V. A. (2023). Formulation and evaluation of nanosized hippadine-loaded niosome: Extraction and isolation, physicochemical properties, and in vitro cytotoxicity against human ovarian and skin cancer cell lines. Journal of Drug Delivery Science and Technology, 87, 104766–104766. https://doi.org/10.1016/j.jddst.2023.104766
• Pamu Sandhya, Pamu Poornima, & Darna V.R.N. Bhikshapathi. (2020). Self Nanoemulsifying Drug Delivery System of Sorafenib Tosylate: Development and In Vivo Studies. Pharmaceutical Nanotechnology, 8(6), 471–484. https://doi.org/10.2174/2211738508666201016151406
• Parvathaneni, V., Goyal, M., Kulkarni, N. S., Shukla, S. K., & Gupta, V. (2020). Nanotechnology Based Repositioning of an Anti-Viral Drug for Non-Small Cell Lung Cancer (NSCLC). Pharmaceutical Research, 37(7). https://doi.org/10.1007/s11095-020-02848-2
• Paswan, S. K., Saini, T. R., Jahan, S., & Ganesh, N. (2021). Designing and Formulation Optimization of Hyaluronic Acid Conjugated PLGA Nanoparticles of Tamoxifen for Tumor Targeting. Pharmaceutical Nanotechnology, 9(3), 217–235. https://doi.org/10.2174/2211738509666210310155807
• Porawan Aumklad, Phuvamin Suriyaamporn, Suwanee Panomsuk, Boonnada Pamornpathomkul, & Praneet Opanasopit. (2024). Artificial intelligence-aided rational design and prediction model for progesterone-loaded self-microemulsifying drug delivery system formulations. Science, Engineering and Health Studies, 24050002–24050002. https://doi.org/10.69598/sehs.18.24050002
• Qushawy, M. (2021). Effect of the Surfactant and Liquid Lipid Type in the Physico-chemical Characteristics of Beeswax-based Nanostructured Lipid Carrier (NLC) of Metformin. Pharmaceutical Nanotechnology, 9(3), 200–209. https://doi.org/10.2174/2211738509666210222143716
• Sahu, R., Dixit, S., Verma, R., Duncan, S. A., Coats, M. T., Giambartolomei, G. H., Singh, S. R., & Dennis, V. A. (2020). A nanovaccine formulation of Chlamydia recombinant MOMP encapsulated in PLGA 85:15 nanoparticles augments CD4+ effector (CD44high CD62Llow) and memory (CD44high CD62Lhigh) T-cells in immunized mice. Nanomedicine: Nanotechnology, Biology and Medicine, 29, 102257. https://doi.org/10.1016/j.nano.2020.102257
• Sarkar, S., Dyett, B., Lakic, B., Ball, A. S., Yeo, L. Y., White, J. F., Soni, S., Drummond, C. J., & Conn, C. E. (2023). Cubosome Lipid Nanocarriers As a Drug Delivery Vehicle for Intracellular Mycobacterium tuberculosis Infections. ACS Applied Materials & Interfaces, 15(18), 21819–21829. https://doi.org/10.1021/acsami.3c00101
• Sharma, S., Sudan, P., Arora, V., Goswami, M., & Dora, P. (2021). Nanotechnological Advances for Nutraceutical Delivery. Nanotechnology, 149–182. https://doi.org/10.1201/9781003120261-5
• Song, P., Du, W., Li, W., Zhu, L., Zhang, W., Gao, X., Tao, Y., & Ge, F. (2020). Preparation, characterization, and in vitro evaluation of amphiphilic peptide P12 and P12-DOX nanomicelles as antitumor drug carriers. Nanomaterials and Nanotechnology, 10, 184798042091151. https://doi.org/10.1177/1847980420911519
• Soni, P. K., & Saini, T. R. (2021). Purification of Drug Loaded Liposomal Formulations by a Novel Stirred Cell Ultrafiltration Technique. Pharmaceutical Nanotechnology, 9(5), 347–360. https://doi.org/10.2174/2211738509666211124145848
• The Potential of DNA Nanotechnology to Advance Multiple Therapeutic Systems. (2023). Therapeutic Delivery. https://doi.org/10.4155//tde-2023-0060
• Thi, T., Tran, T. H., Huang, C.-Y. F., & Nguyen, C. N. (2022). Application of Computational Screening Tools and Nanotechnology for Enhanced Drug Synergism in Cancer Therapy. Current Drug Delivery, 20(7), 1015–1029. https://doi.org/10.2174/1567201819666220426092538
• Tripathi, S. K., Patel, B., Shukla, S., Pachouri, C., Pathak, S., & Pandey, A. (2021). Donepezil loaded PLGA Nanoparticles, from Modified Nano-Precipitation, an Advanced Drug Delivery System to treat Alzheimer Disease. Journal of Physics: Conference Series, 1849(1), 012001. https://doi.org/10.1088/1742-6596/1849/1/012001
• Tuğba Eren Böncü, & Ozdemir, N. (2022). Effects of drug concentration and PLGA addition on the properties of electrospun ampicillin trihydrate-loaded PLA nanofibers. Beilstein Journal of Nanotechnology, 13, 245–254. https://doi.org/10.3762/bjnano.13.19
• Vakhariya, R. R., Salunkhe, V. R., Randive, D. S., Bhutkar, M. A., & Bhinge, S. D. (2019). Design, Development and Optimization of Ramipril Solid Lipid Nanoparticles Using Solvent Emulsification and Evaporation Method. Nanoscience & Nanotechnology-Asia, 11(1), 42–52. https://doi.org/10.2174/2210681209666191204113659
• Virmani, R., & Pathak, K. (2022). Consumer Nanoproducts for Cosmetics. Handbook of Consumer Nanoproducts, 931–961. https://doi.org/10.1007/978-981-16-8698-6_58
• Wazid, Meer Zeshanul. (2024). Nanotechnology: revolutionizing drug delivery, diagnostics, and therapeutics. Bracu.ac.bd. https://doi.org/9789849906995
• Zwain, T., Taneja, N., Suha Zwayen, Aditi Shidhaye, Aparana Palshetkar, & Singh, K. K. (2021). Albumin nanoparticles—A versatile and a safe platform for drug delivery applications. Elsevier EBooks, 327–358. https://doi.org/10.1016/b978-0-12-820757-4.00008-9

Read Related Articles